Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ovation ScienceOVATF 3-Year EPS without NRI Growth Rate is 12.60% as of Mar. 2026, which is at its 10-year median of 12.60. The stock has 4 warning signs investors should review. Among 788 Drug Manufacturers companies, Ovation Science ranks better than 56.47% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 12.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 14.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of Ovation Science was 22.70% per year. The lowest was 1.30% per year. And the median was 12.60% per year.
Ovation Science (OTCPK:OVATF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ovation Science 3-Year EPS without NRI Growth Rate Related Terms
OVATF vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovation Science 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ovation Science's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ovation Science's 3-Year EPS without NRI Growth Rate falls into.
Ovation Science 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 12.60% mean?
Ovation Science (OVATF) has a 3-Year EPS without NRI Growth Rate of 12.60% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ovation Science and its competitors. This is near median its historical median of 12.60. Over the past decade, Ovation Science's 3-Year EPS without NRI Growth Rate has ranged from 1.30 to 22.70. According to the industry distribution chart, Ovation Science ranks #343 out of 788 companies in the Drug Manufacturers industry, placing it in the top 43.5%.
Is Ovation Science's 3-Year EPS without NRI Growth Rate too high?
Ovation Science's current 3-Year EPS without NRI Growth Rate of 12.60% is near median its 10-year median of 12.60. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 22.70. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.60. Ovation Science's value of 12.60% is 31.3% above this industry median. Based on the distribution chart, Ovation Science ranks #343 out of 788 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Ovation Science's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ovation Science ranks #343 out of 788 companies for 3-Year EPS without NRI Growth Rate. This puts Ovation Science in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.60. Ovation Science's value of 12.60% is 31.3% above this benchmark. Historically, Ovation Science's own 3-Year EPS without NRI Growth Rate has ranged from 1.30 to 22.70 over the past decade. While the company's 10-year median is 12.60 vs. the industry median of 9.60, Ovation Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ovation Science's current 3-Year EPS without NRI Growth Rate of 12.60% is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ovation Science and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovation Science's current 3-Year EPS without NRI Growth Rate is 12.60%, which is near median its own 10-year median of 12.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovation Science stock overvalued right now?
Based on GuruFocus' analysis, Ovation Science (OVATF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.03, compared to a current price of $0.01 — trading 75% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 12.60%, which is near median its 10-year median of 12.60 and 31.3% above the Drug Manufacturers industry median of 9.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ovation Science (OVATF), the current 3-Year EPS without NRI Growth Rate is 12.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ovation Science Inc. is a Canada-based company mainly engaged in the business of providing topical and transdermal cannabis products under the Ovation brand label, utilizing patented Invisicare delivery technology. The Company operates in one reportable operating segment, the sub-licensing and sales of cannabis products that utilize Invisicare, a patented polymer-based technology for topical and transdermal skin care products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVATF has been successfully added to your 
